Je dividenda Nippon Shinyaku Co bezpečná?
Nippon Shinyaku Co zvyšuje dividendu už 5 rokov.
V priebehu posledných 10 rokov Nippon Shinyaku Co ročne 17,848 % zvýšená.
Na 5-ročnú perspektívu vzrástol výplata o 8,101 %.
Analytici očakávajú pre bežný obchodný rok nárast o Rast dividend vo výške 4,532%.
Nippon Shinyaku Co Aktienanalyse
Čo robí Nippon Shinyaku Co?
Nippon Shinyaku Co Ltd is a Japanese company that operates in the pharmaceutical industry. The company was founded in 1919 and has its headquarters in Kyoto, Japan. Since its inception, the company has been dedicated to developing innovative and high-quality medications that contribute to improving the health and well-being of patients worldwide. The business model of Nippon Shinyaku Co Ltd focuses on the development, production, and marketing of drugs based on organic chemical compounds. The company is built around the concepts of "innovation, balance, and responsibility" and aims to improve people's lives through innovative research and development of new medications. It operates in various divisions including pharmaceuticals, diagnostics, and medical devices. Within the pharmaceuticals division, the company primarily focuses on developing medications for the treatment of cancer, inflammation, and neurodegenerative diseases. In the diagnostics division, Nippon Shinyaku Co Ltd develops test reagents and platforms to support the diagnosis of various diseases. The company also develops medical devices such as insulin pumps and cardiovascular implants. Nippon Shinyaku Co Ltd offers a variety of products categorized into different therapeutic categories. Its key products include the cancer drug Firdapse for the treatment of Lambert-Eaton myasthenic syndrome, the anti-inflammatory drug Tazverik for the treatment of soft tissue sarcomas, and the Alzheimer's drug Memary. The company has also developed medications for the treatment of asthma, rheumatoid arthritis, and other diseases. Research and development of new medications are highly valued by the company. It has collaborated with government agencies and academic institutions in recent years to develop new drugs and conduct clinical trials. Nippon Shinyaku Co Ltd aims to be a global leader in the development of new medications and diagnostic platforms. The company also has a global presence, distributing its products in Asia, Europe, and North America. It has formed strategic partnerships with various companies to accelerate the development and marketing of new medications. Overall, Nippon Shinyaku Co Ltd is an innovative company that focuses on the development and marketing of drugs, diagnostics, and medical devices. It aims to improve people's lives worldwide by developing innovative and high-quality products. The company will continue to focus on research and development of new medications to solidify its position as a leading company in the pharmaceutical industry worldwide. Nippon Shinyaku Co je jednou z najobľúbenejších spoločností na Eulerpool.com.Investičné plány do akcií ponúkajú atraktívnu možnosť pre investorov na dlhodobú výstavbu majetku. Jednou z hlavných výhod je tzv. Cost-Average-Effekt: Pravidelnou investíciou pevnej sumy do akcií alebo do akciových fondov automaticky kupujete viac podielov, keď sú ceny nízke, a menej, keď sú vysoké. To môže viesť k výhodnejšej priemernej cene za podiel v priebehu času. Okrem toho investičné plány do akcií umožňujú aj malým investorom prístup k drahým akciám, keďže sa dá investovať už s malými sumami. Pravidelná investícia tiež podporuje disciplinovanú investičnú stratégiu a pomáha predchádzať emocionálnym rozhodnutiam, ako je impulzívne kupovanie alebo predávanie. Ďalej investorom prináša potenciálny nárast hodnoty akcií, ako aj výplaty dividend, ktoré môžu byť reinvestované, čo zvyšuje efekt zloženého úroku a tým rast investovaného kapitálu.